Εμφάνιση απλής εγγραφής

dc.creatorDaniil, Z. D.en
dc.creatorPapageorgiou, E.en
dc.creatorKoutsokera, A.en
dc.creatorKostikas, K.en
dc.creatorKiropoulos, T.en
dc.creatorPapaioannou, A. I.en
dc.creatorGourgoulianis, K. I.en
dc.date.accessioned2015-11-23T10:25:07Z
dc.date.available2015-11-23T10:25:07Z
dc.date.issued2008
dc.identifier10.1016/j.pupt.2006.10.005
dc.identifier.issn1094-5539
dc.identifier.urihttp://hdl.handle.net/11615/26885
dc.description.abstractBackground: Idiopathic Pulmonary fibrosis (IPF) is a fatal illness characterized by progressive fibrosis resulting in severe dyspnea and impairment Of lung function. Although the mechanisms by which lung fibrosis develops are not fully ascertained, recent findings suggest that oxidative stress may play an important role in the pathogenesis of tissue fibrosis. Aim: To evaluate the oxidative stress in the serum of patients with IPF and to explore the relationship between oxidative stress levels, dyspnea and impairment of lung function. Material and methods: Blood samples from 21 untreated patients with IPF, sequentially recruited over a period of 2 years, and 12 controls were analyzed. The level of oxidative stress in the blood was determined through a spectrophotometric procedure (D-ROMs test). FVC and DLCO were measured in all patients. The level of dyspnea was assessed by the Medical Research Council (MRC) chronic dyspnea scale. Results: Serum levels of oxidative stress were significantly increased in patients with IPF compared to controls (mean +/- SEM: 356.8 +/- 14 and 201 +/- 10 Carratelli units respectively, p<0.001). Oxidative stress was negatively associated with FVC (p<0.01, r = -0.79) and with DLCO (p<0.01, r = -0.75). Furthermore, oxidative stress was significantly correlated with MRC dyspnea score (p<0.01, r = 0.87). Oxidative stress measurements were highly reproducible oil two consecutive measurements in the same patients. Conclusion: The levels of systemic oxidative stress are enhanced in patients with IPF and could provide useful information about the classification of IPF severity. Strategies to reduce the oxidant burden in IPF may be beneficial in reducing the progressive deterioration of these patients. (C) 2006 Elsevier Ltd. All rights reserved.en
dc.sourcePulmonary Pharmacology & Therapeuticsen
dc.source.uri<Go to ISI>://WOS:000262943300005
dc.subjectIdiopathic pulmonary fibrosisen
dc.subjectOxidative stressen
dc.subjectMedical researchen
dc.subjectcouncil chronic dyspnea scaleen
dc.subjectLung functionen
dc.subjectWORKING PARTY STANDARDIZATIONen
dc.subjectEUROPEAN RESPIRATORY SOCIETYen
dc.subjectINTERSTITIAL LUNG-DISEASESen
dc.subjectOFFICIAL STATEMENTen
dc.subjectREACTIVE OXYGENen
dc.subjectPATHOGENESISen
dc.subjectCELLSen
dc.subject8-ISOPROSTANEen
dc.subjectCOMMUNITYen
dc.subjectPRODUCTSen
dc.subjectPharmacology & Pharmacyen
dc.subjectRespiratory Systemen
dc.titleSerum levels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosisen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής